Bramwell V H, Holdener E E, Siegenthaler P, Ten Bokkel Huinink W, Bruntsch U, Renard J, van Glabbeke M
Eur J Cancer Clin Oncol. 1984 Jun;20(6):753-9. doi: 10.1016/0277-5379(84)90212-8.
Forty-three patients with advanced measurable lymphoma, progressive after conventional therapy, were entered into a phase II study of m-AMSA 90-120 mg/m2 every 3 weeks. Five patients were ineligible and response could not be evaluated in four patients. For HD there were two partial responses (14%), lasting 6 and 41 weeks, in 14 evaluable patients. Among 20 evaluable patients with NHDL three (15%) achieved partial remission, but duration of response could not be evaluated. One patient with diffuse histiocytic lymphoma died of infection at 4 weeks, a second with lymphoblastic lymphoma was given high-dose steroids commencing at 6 weeks, and the third patient with nodular poorly differentiated lymphocytic lymphoma refused further treatment after one course. Leucopenia was more marked in patients with NHDL (WBC nadir X 10(9)/l, median 2.2, range 0.2-4.3) than in HD (WBC nadir X 10(9)/l, median 2.8, range 0.85-7.2), as was thrombocytopenia. There was one toxic death and one life-threatening infection, both secondary to myelosuppression. Non-haematological toxicity was mild. m-AMSA has marginal activity in previously treated lymphomas and causes considerable myelosuppression.
43例晚期可测量淋巴瘤患者，在接受传统治疗后病情进展，进入一项II期研究，每3周静脉注射氨苯吖啶90 - 120mg/m²。5例患者不符合入组条件，4例患者的疗效无法评估。对于霍奇金淋巴瘤（HD），14例可评估患者中有2例部分缓解（14%），缓解持续时间分别为6周和41周。在20例可评估的非霍奇金淋巴瘤（NHDL）患者中，3例（15%）达到部分缓解，但缓解持续时间无法评估。1例弥漫性组织细胞淋巴瘤患者在4周时死于感染，1例淋巴细胞性淋巴瘤患者在6周时开始接受大剂量类固醇治疗，第3例结节性低分化淋巴细胞淋巴瘤患者在一个疗程后拒绝进一步治疗。NHDL患者的白细胞减少比HD患者更明显（白细胞最低点×10⁹/L，中位数2.2，范围0.2 - 4.3），血小板减少也是如此。有1例因毒性死亡和1例危及生命的感染，均继发于骨髓抑制。非血液学毒性较轻。氨苯吖啶在先前治疗过的淋巴瘤中具有边缘活性，并会引起相当程度的骨髓抑制。
